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Background: Reactivation of latent varicella zoster virus, partly due to age-related immunosenescence and
immunosuppressive conditions, results in herpes zoster (HZ) and its associated complications. The management
of the most important complication, post-herpetic neuralgia (PHN), is challenging, particularly in the elderly, and is
generally unsatisfactory. No previous reviews have reported the incidence of HZ-associated mortality.
Methods: We carried out a systematic literature review to identify studies and databases providing data for
HZ-associated mortality in adults aged ≥50 years in Europe.
Results: We identified 12 studies: Belgium (1); France (1); Germany (1); the Netherlands (2); Portugal (1); Spain (4)
and England/Wales (2) and 4 databases from Europe: France; Germany and England/Wales. The incidence was
available from eight studies; it was highest in those aged ≥95 in France (19.48/100,000). In the European (WHO)
database, the overall mortality ranged from 0 to >0.07/100,000. The age- and gender-specific HZ mortality rates
from the other databases showed that while in younger age groups the HZ mortality rate was higher in males,
in older patients the rate was much higher in women. The case fatality rate was 2 and 61/100 000 in those 45–65
and ≥65 years, respectively. A similar increase with age was seen for the hospital fatality rate; 0.6% in those 45–65
years in the UK and 7.1% in those ≥80 in Spain.
Conclusions: Although the data were sparse and heterogeneous, HZ-associated mortality clearly increases with
age. In addition, the elderly who develop HZ often have underlying diseases and are at increased risk of functional
decline and loss of independence. Mortality should be taken into account in health-economics models.
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Varicella-zoster virus (VZV) is a herpes virus that infects
nearly all humans and causes two distinct diseases: vari-
cella, the primary infection which usually occurs in child-
hood, and herpes zoster (HZ) which is the result of the
reactivation of VZV which remains latent in the sensory
ganglia following primary infection. This reactivation oc-
curs when VZV-specific cellular-mediated immunity de-
creases, mainly due to age-related immunosenescence and
immunosuppressive conditions.
HZ is characterized by a vesicular skin rash localized
in the sensory region of the affected ganglia, and is often
preceded, or accompanied by acute pain or itching. The
individual lifetime risk of developing HZ is between 24%* Correspondence: hbricout@spmsd.com
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unless otherwise stated.and 30%, or approximately 1 in 4 people [1-5]. However,
for individuals aged 85 and over, this risk increases to 1 in
2 [6]. HZ incidence increases markedly after 50 years of
age, with two-thirds of HZ cases occurring in individuals
aged 50 years and over [7]. Anyone who has had varicella
is at risk of HZ; in Europe varicella affects over 90% of
children before the age of 15 [8].
HZ is painful during the acute phase, but pain may
persist for months or even years. Post-herpetic neuralgia
(PHN), defined as chronic pain persisting after rash onset,
occurs in 20% to 50% of patients, and can lead to several
months of treatment and loss of quality of life [9,10]. After
1 year, almost 10% of patients, mainly older people, still
have persistent pain [11,12].
A recent literature review showed that the annual HZ
incidence is similar throughout Europe, varying from 2.0
to 4.6/1 000 person-years, with no clear geographic trend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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children <10 years, around 2/1 000 adults aged <40 years,
and around 1–4/1 000 adults aged 40–50 years, increasing
to around 7–8/1 000 after age 50 years, up to 10/1 000
after 80 years of age. This review confirmed that, in
Europe, HZ incidence increases with age, particularly after
50 years of age [13]. Similarly, data on the percentage of
HZ cases who develop PHN are available across EU [14].
PHN, defined as HZ-associated pain lasting for at least
three months, has been reported to occur in 10% to 20%
of patients. However, the prevalence and severity of
PHN increases with age, and has been reported to be as
high as 60% to 70% of patients aged ≥60 [14]. In people
aged over 50 years, there is a higher rate of HZ-associated
hospitalization and HZ and PHN have a greater impact on
the quality of life of patients and their relatives.
To date, a review of the data for HZ-associated mor-
tality has not been published. To fill this gap and to have
a complete picture of the burden of HZ and PHN, we
performed a systematic literature review of data on HZ-
associated mortality in people aged ≥50 years in Europe.
Methods
Objectives
The objective of this systematic literature review was to
summarize the available data on the HZ-associated mor-
tality in adults aged ≥50 years in Europe.
Search strategy
We searched PubMed from 1st January 1990 to 31
October 2013 using a combination of the following search
terms as free text and medical subheading (MeSH) terms:
mortality; death; case fatality rate; hospital fatality rate;
Herpes Zoster [MeSh]; Herpes Zoster Ophthalmicus
[MeSh]; Herpes Zoster Oticus [MeSh]; Encephalitis,
Varicella Zoster [MeSh]; shingles, herpes zoster. We also
scanned reference lists in selected publications to identify
additional references, including publications known to the
authors, not indexed on PubMed. No language restrictions
were used.
In addition, European surveillance data, such as the
European Detailed Mortality Database (DMDB) [15], na-
tional surveillance data, such as the CépiDc database
from INSERM [16], the Office for National Statistics for
England and Wales [17] and the German Federal Health
Monitoring System [18] and the websites of the national
health institutes and sentinel networks were searched.
The literature search was performed by one author
(MH). The search results were downloaded into EndNote®
for screening.
Inclusion and exclusion criteria
We included publications or websites/databases that
provided HZ-associated mortality data for adultsaged ≥50 years, irrespective of their health status, in any
of the following European Union (EU) countries: Austria;
Belgium; Bulgaria; Croatia; Cyprus; Czech Republic;
Denmark; Estonia; Finland; France; Germany; Greece;
Hungary; Ireland; Italy; Latvia; Lithuania; Luxembourg;
Malta; the Netherlands; Norway; Poland; Portugal;
Romania; Slovakia; Slovenia; Spain; Sweden; Switzerland;
and United Kingdom. Case reports were excluded.
The HZ-associated mortality data could include: total
number of HZ deaths; HZ-mortality incidence; HZ case
fatality rate (CFR) or hospital fatality rate (HFR). The
CFR was defined as the percentage of those who died
among community-based cases and the HFR as the per-
centage of those who died among hospitalized cases.Study selection process
The first round of screening was performed on the titles
and abstracts by one author (MH) and another author
(HB) verified the included and excluded publications.
Full papers were obtained for the second round of screen-
ing that was performed by one author (MH) and verified
by another (HB). The reasons for exclusion from this
screening round were recorded (using broad categories,
e.g. data not available for adults >50; population outside
the defined EU countries). The search results were
summarised using the PRISMA flow diagram (Figure 1)
[19]. Papers reporting HZ-associated mortality data for
countries outside Europe were kept for comparisons
and discussion.Quality assessment of included studies
As it was expected that there would not be many studies
reporting HZ mortality rates, we decided to include all
available data, without restrictions based on quality and to
describe the quality of the data.Data analyses
The following data were extracted from the included
studies by one author (MH) and verified by another
author (HB): country, date, data source, HZ diagnosis,
mean age at HZ related death, presence of comorbidi-
ties and HZ mortality related data. In some studies
where the available data allowed for estimation, the
CFR or HFR were calculated by dividing the number of
deaths by the number of HZ cases in the community or
by the number of patients hospitalized with HZ, re-
spectively. In addition, in studies where only the annual
number of death at the national level was available, the
age-specific mortality rate was estimated by obtaining
the country age-specific population from the EuroStats
database [20].
Figure 1 PRISMA diagram - summary of search results.
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Data sources identified
A total of 568 references were identified on PubMed and
2 were identified by the authors (Figure 1). Following
removal of duplicate publications, 557 abstracts were
first screened on titles and abstracts and 484 refer-
ences were excluded. Full papers were obtained for
the remaining 73 references; 12 of these satisfied the
inclusion criteria for this review. The reasons for
non-inclusion were: no HZ-associated mortality data
available (31); not European data (18); not possible
to have data for adults aged ≥50 years (8); only vari-
cella (4).
The 12 studies included were from 7 countries: Belgium
(1); France (1); Germany (1); the Netherlands (2); Portugal
(1); Spain (4) and England and Wales (2) (Table 1)
[2,21-31]. In addition, we identified four databases that
provided HZ-associated mortality data from Europe (1);
France (1); Germany (1) and England and Wales (1)
(Table 2) [15-18]. A number of other mortality data-
bases were identified but it was not possible to extract
HZ-specific mortality [32].Characteristics of studies and databases
Published studies
All the studies used databases to identify HZ-related
deaths (Table 3). Five studies used national statistics data-
bases that collected data from death certificates for the
general population [21,23,27,30,31]. Four of the remaining
studies used national hospital statistics databases, two
used both types of database and the last used data from a
drug safety register, BIOBADASER, that monitors patients
with rheumatic diseases treated with biological agents in
100 Spanish health centres [2,22,24-26,28,29]. Three stud-
ies reported mortality data specifically for patients with
underlying conditions [26,27,29]. Four studies presented
mortality data for deaths with HZ as the primary cause,
one with HZ as the primary diagnosis at hospital admis-
sion and three with HZ as primary or associated cause;
the remaining four studies did not specify if HZ was the
primary or associated cause. Five studies used International
classification of diseases-10 (ICD-10) codes and five used
ICD-9 codes to identify HZ-associated deaths. The study
in Spain using a drug safety database was the only one
that reported the use of microbiological confirmation of
Table 1 Characteristics of included studies
Study ID [ref] Country/Dates Data source HZ diagnosis Age (years) Comorb y HZ-associated mortality
data available or
calculated*
Bilcke 2012 [21] Belgium/1990-2007 National death certificates Code for HZ as possible
cause of death (no indication
of primary or associated) and
independent evaluation by 5
experts
≥60 None Overall incidence
Gonzalez Chiappe
2010 [27]








21.6% ha 1 underlying
condition 9.6%
malignan s, 12.5% diabetes,
10.9% bl dyscrasias and
some im ne deficiencies)
Age-specific incidence;
disease-specific number of
HZ deaths and hospital
fatality rate*
Ultsch 2011 [30] Germany/2007-2008 Federal Health Monitoring
database
ICD-10 codes of primary
disease
≥50 None Overall, and age- and
gender-specific incidences
and hospital fatality rate*
van Lier 2010 [31] Netherlands/2000-2007 National Statistics (CBS)
database
ICD-10 codes B02 and G530
as primary cause of death
92% of deaths in ≥75 None Number of HZ deaths;
incidence of HZ mortality*
de Melker 2006 [23] Netherlands/1996-2002 National Statistics (CBS)
database
ICD-10 code B02 as primary
cause of death
97% in ≥60 None Number of VZV deaths,
incidence of HZ mortality*
Mesquita 2013 [28] Portugal/2000-2010 National Health Hospital
Ministry Database
IDC-9 codes 053.10-13,
053.19-22, 053. 29, 053.71,
053.79, 053.8, 053.9 as
primary diagnosis at hospital
admission
All ages, with 10-year
groups from 50 to 99
None In-hospital fatality rate (not
available by gender)
Perez-Sola 2011 [29] Spain/2000-2006 Registry for drug safety in
rheumatic patients treated
with anti-TNF (100 Spanish
health centres)
Microbiological diagnosis 50 (mean; SD = 14) Rheumat iseases treated
with TNF tagonists
Number of HZ deaths
Gil 2009 [24] Spain/1998-2004 National hospital discharge
database (CMBD)
ICD-9 code for primary or
secondary diagnosis: 0.53,
053.0-053.9
68.3 (SD = 15.5) for
hospitalisations




Gil-Prieto 2011 [26] Spain/1998-2004 National hospital discharge
database (CMBD)
ICD-9 code for primary or
secondary diagnosis (053;
053.0-053.9)







Gil-Prieto 2012 [25] Spain/1997-2008 National hospital discharge
database (CMBD)
ICD-9-CM code for primary or







Number of HZO deaths; HZO
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Table 1 Characteristics of included studies (Continued)




& Office for National Statistics
(death certificates)
ICD-10 code B02 as primary
diagnosis and ICD Code for
HZ as cause of death
45-64; 65+ 8% with underlying
conditions
Number of HZ deaths; Age-
specific incidence; hospital-
fatality rate





& Office for National Statistics
(death certificates)
ICD-10 code B02 in any of
the 7 diagnosis fields/ICD-9
code 053 death (no details
for primary or associated)
45+; and 5-year
sub-groups
None Age-specific mortality and
case fatality rate













Table 2 Characteristics of included surveillance systems/databases
Database name [Ref] Region/dates covered HZ diagnosis HZ-associated mortality
data available
WHO-DMDB [15] Europe/2010, except Belgium and
France: 2009




CépiDc [16] France/2010 ICD-10 code: B02 for primary
cause of death
Age-specific incidence
Federal Health Monitoring System [18] Germany/2011 and previous years ICD-10 code: B02 and sub-codes Number and incidence for
overall and sex by year
Office for National Statistics [17] England and Wales/2012 ICD-10 code: B02 and sub-codes
for underlying cause of death
Age-specific incidence
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no information on the use of microbiological confirm-
ation of the HZ diagnosis was provided. Some hospital-
based studies reported underlying conditions: one in
France reported that 22% of patients had ≥1 underlying
conditions and another in Spain reported that 25% of
the patients were immunocompromised but they did
not provide mortality data for these patients separately
[25,27]. Eight of the studies provided age-specific HZ-
associated mortality data [2,22,24-28,30].
Databases
We identified four databases that provided age-specific
HZ mortality data (Table 2) [15-18]. Three of these data-
bases were country-specific (France, Germany and United
Kingdom (England and Wales)); the fourth database pro-
vided data for all European countries. As the national data-
bases all contributed their data to the European database,
we did not analyse their data, but extracted the data from
the European database. This European database used Inter-
national Statistical Classification of Diseases and Related
Health Problems 10th Revision (ICD-10) code (B02) for all
countries included in this review, except for Greece, which
used ICD-9 codes, but there was no HZ mortality data
available for Greece. We extracted HZ mortality data cor-
responding to people aged ≥50 years on 7 March 2014.
HZ-associated mortality
Overall and age-specific incidence rates
Eight of the studies provided HZ-mortality rates or pro-
vided data that could be used to estimate the mortality
rates [2,21-23,27,28,30,31]. The age groups used were dif-
ferent between the studies but the overall trend was always
towards a higher mortality incidence rate in the older age
groups (Figure 2A). The mortality rates ranged from 0 in
those aged 55–59 years in Germany to 19.5/100 000 for
those aged ≥95 years in France [27,30].
The data from the World Health Organisation (WHO)
database showed that the estimates for the overall HZ mor-
tality incidence in those aged ≥50 years varied widely be-
tween the countries for which estimates were available in
2011, ranging from 0.002 in Poland to 0.070 per 100 000 inDenmark, with a median of 0.039 per 100 000 (Figure 3)
[15]. In countries where data are available for >1 year,
although there were variations over time there did not
seem to be any particular increasing or decreasing
trends in the HZ mortality rate overall or for those aged
50–69 or ≥70 years (data not shown). The HZ mortality
rate varied by gender and was generally higher in women,
although in Spain, Italy, France and, particularly, Denmark,
the mortality rate was higher in men (Figure 4).
Despite the between-countries differences in rates, there
was a trend towards higher mortality rates in older age
groups in all countries, with the increase occurring from
the age of 70–74 years (Figure 5).
Age-specific case fatality and hospital fatality rates
Eight of the studies provided data to be used to estimate
age-specific CFR (3), HFR (4) both (1) [2,22,24-28,30].
The age groups analysed varied between the studies but
the overall trend was towards much higher rates in older
age groups. The studies from UK provided estimation of
CFRs that were around 2/100 000 in those aged 45 to
65 years old; and 61/100 000 in those aged ≥65. The
CFR was available in four studies and varied from 0 in
those aged 55–59 years in Germany to 2.02% in those
aged ≥85 years in England and Wales (Figure 2B). The
HFR was available in five studies and varied from 0.4%
in those aged 60–69 years in Portugal to 7.1% in those
aged >80 years in Spain (Figure 2C). The HFRs reported
in Spain were higher than in other countries where the
HFR was generally under 1% until the age of 75 to 85 years.
Data from the two studies that provided fatality rates for
sub-groups of patients with underlying conditions showed
that there was a higher fatality rate in these populations
[26,27]. In one of the studies, the fatality rate was also re-
ported to increase with age in these populations [26]. One
study in patients with ophthalmic HZ reported HFRs of
2.5% and 1.6% in those aged ≥50 in the overall population
and in immunocompetent patients, respectively [25].
Discussion
The results from this review show that HZ-associated
mortality rate is generally low and, that despite the data
Table 3 HZ mortality data from included studies
Study (ref) Country Period Age (years) Age at HZ-related
death
Mortality incidence/










France 2000-2007 Overall 96.8% (1360; 170/year)
in those aged ≥65
years
0.286 (0.244-0.328) 0.075 2.012 1 405 (176 ± 13/year)
≥65 4.36 ± 0.20
45-54 0.031 (0–0.069) 0.007
55-64 0.072 (0.009-0.135) 0.012
65-74 0.236 (0.102-0.370) 0.027
75-84 1.25 (0.90-1.60) 0.127
85-94 7.24 (5.66-8.82) 0.672
≥95 19.48 (11.50-27.47) 1.356 HFR: Malignancies: 4.236
(449/10 599) HIV/AIDS:
0.357 (26/7 277)
Diabetes: 1.654 (94/5 682)
Blood dyscrasias: 3.907
(82/2 099)





Ultsch 2011 [30] Germany 2007-2008 50-54 73% (n = 48) deaths in
≥80 years
0.02 (0.00-0.10) 0.003 1
55-59 0.00 NA 0 0
60-64 0.02 (0.00-0.13) 0.003 1
65-69 0.06 (0.01-0.17) 0.005 3
70-74 0.11 (0.04-0.27) 0.010 5
75-79 0.30 (0.14-0.57) 0.025 9
80-84 0.54 (0.28-0.94) 0.043 12
85-89 1.20 (0.67-1.98) 0.096 15
≥90 3.86 (2.36-5.96) 0.293 20
Overall 0.21 (0.16-0.26) 0.022 66
van Lier 2010 [31] Netherlands 2000-2007 ≥60 92% deaths occurred in
≥ 75 years
0.59 (estimated with















Table 3 HZ mortality data from included studies (Continued)
de Melker 2006 [23] Netherlands 1996-2002 ≥75 97% occurred in
≥60 years
1.92 (estimated with









Perez-Sola 2011 [29] Spain 2000-2006 0




Gil-Prieto 2011 [26] Spain 1998-2004 50-59 3.0*/1.1
60-69 2.7*/1.7
≥70 5.3*/2.7



























Table 3 HZ mortality data from included studies (Continued)
Gil-Prieto 2012 [25] Spain 1997-2008 First diagnosis
≥50§ 2.51§ (1.42-3.61)/ 20
≥50# 1.62# (0.67-2.5) 11
50-59
60-69 0/0 0§/0#











Brisson 2003 [22] England & Wales 1991-2000 45-64$ 0.014 0.002 0.612 2$
≥65$ 0.566 0.061 3.190 47
all ages$$ 0.094 0.031 2.722) 49






















Figure 2 Mortality data from published studies: A) HZ mortality rate by age (years); B) HZ case fatality rate by age (years); C) HZ hospital fatality
rate by age (years).
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with age. Globally HZ-associated mortality is very low
(<0.1/100 000) in those aged under 70 to 75 years andincreases in older people, reaching between 1.2 to 7.2/
100 000 in those aged ≥85 years. Not all studies reported
trends in HZ mortality incidence over time, but one
Figure 3 Age-standardized HZ mortality rate per 100 000 in all adults aged ≥50 years [15].
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HZ-associated mortality over the 90's [22]. The overall
EU data from the Detailed Mortality Database (DMDB)
showed variations over time for those aged 50–69 years
and those aged ≥70 years. However, the HZ mortality
rate did not appear to increase or decrease from 1994
to 2012.
Similar to the EU data reported here, data from the
US, for 1979 to 2007, showed that the HZ mortality rate
was higher in older patients; an average of 134 deaths
were recorded with HZ as the underlying cause, and 45%
of these occurred in those aged ≥85 years [33]. The overallFigure 4 Age-standardized HZ mortality rate per 100 000 in females (left) aage-adjusted HZ-mortality was reported to decrease by
42% from 7.8 to 4.5 per 100 000. In another study in the
US, from 1986 to 1995 the overall HZ-HFR was 5.3%; in
those with underlying conditions the HFR was 8.7%,
compared with 3.7% in those without [34]. In Australia,
it was also reported to be higher in older people and
women; 219 of the 238 (92%) deaths with HZ as the pri-
mary cause recorded from 1971 to 1993; (219) were in
people aged >65 years and 65% were women [35]. Also
the overall crude HZ mortality incidence was stable over
this period (0.068 per 100 000); 0.043 and 0.092 per 100 000
in men and women, respectively. In another study innd males (right) aged ≥50 years [15].
Figure 5 Age-standardized HZ mortality rate per 100 000 in adults by age group in the European countries [15].
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was 4% (186/4718) [36]. The HFR was higher in those with
HZ as a secondary diagnosis compared with those with HZ
as a primary diagnosis: 6% vs. 1%.
Mortality rates were higher when HZ was reported to
be an associated or secondary cause of death suggesting
that the HZ episode could have an indirect role in mor-
tality [37]. Underlying comorbidities can increase the
severity of the HZ episode and thus the risk of mortality
[24]. It has been estimated that the risk of dying was
five-times higher within three years of HZ reactivation
than in age-matched controls that had not had HZ [27].
Diagnosis of HZ infection can increase the risk of subse-
quent diagnosis of diseases such as cancer, cerebrovas-
cular disease or myocardial infarction and HIV [38-40].
In addition, hospitalisation of elderly people for acute
diseases can result in functional decline and loss of
autonomy [41-43].
It is important to be cautious when making compari-
sons between countries given the differences in study
methodologies and coding practices in each country. Also,
the data are presented for differing age groups, some of
which are very large, making comparisons between studies
difficult. In particular, some data are given for patients
aged ≥65 years when we know that HZ-associated mor-
tality rates are very different between those aged 65 to
75 years and those aged ≥85 years.
The differences in case definitions used could account
for a substantial part of the heterogeneity. Most studies
used clinical diagnosis for HZ, without requiring laboratoryconfirmation. In an elderly population, with many patients
presenting underlying conditions or other comorbidities, it
is difficult for a physician to be certain about the causal
relationship between HZ and death, particularly if the cer-
tifying physician does not have access to all the patient’s
medical records and autopsy results.
It is possible that the variations in the HZ-HFR are
due to differences in the numerator since HZ hospital-
isation rates may vary between countries due to different
healthcare pathways, healthcare seeking behaviours, or
perception of symptoms. In addition, differences in coding
practices could contribute to this heterogeneity. Although
only four studies in this review reported CFRs, there was
less heterogeneity observed; it has been reported that HZ
incidence rates do not vary between European countries
[13]. Other factors such as differences in the prevalence
of underlying risk factors for severe illness, differences
in comorbidity rates or some other unidentified factors
in different populations may also contribute to the ob-
served heterogeneity.
Although most studies used HZ codes on death certifi-
cates for the primary cause of death, some used the codes
for either primary or associated causes of death. Some of
the limitations of using death certificates for estimating
mortality incidence include incompleteness and errors. In
the US, an assessment of the hospital records for dece-
dents, whose death certificate recorded HZ as the under-
lying cause of death, showed that HZ was the underlying
cause in only 52.5% (21/40) of cases and a contributing
cause in another 12.5% (5/40) [33]. Other studies have
Bricout et al. BMC Public Health  (2015) 15:466 Page 13 of 14reported that use of electronic or paper death certificates
can lead to underestimations or overestimates of the true
mortality rate due to other infectious and non-infectious
diseases [44-47].
The strengths of our review include the fact that many
studies and databases provide mortality data from national
databases thus providing data for the whole population.
However, there are some limitations. For example, the
data are not from patient-level longitudinal prospective
studies and, therefore, the retrospective design of the stud-
ies could reduce the accuracy of the data and provide an
underestimation of the burden of HZ mortality. Some
studies only reported mortality with HZ as the primary
cause, whereas it has been suggested that the mortality
is higher when HZ is an associated or contributory
cause of mortality [36]. In addition, there were not
much data available and there was a range of methods
used for the estimations.
Six European Union countries have national surveil-
lance systems and five have sentinel systems for HZ [32].
In the future, access to these surveillance databases should
improve the quality of data concerning the incidence of
HZ in Europe. In addition, the recent initiatives to har-
monise coding for death certificates within Europe should
play an important role in future HZ surveillance pro-
grammes, in particular by improving the comparability of
data sources [48]. The initiatives are important for the
evaluation of the impact of infant varicella vaccination and
adult HZ vaccination on HZ incidence and mortality rates.
Conclusions
In conclusion, although the available data on HZ-associated
mortality are too heterogeneous to allow inter-country
comparisons, they demonstrate that the mortality rate
for HZ is not high, especially in younger people. How-
ever, mortality rates increase with age, particularly in
those aged ≥75 years who often have underlying diseases
and are at risk of functional decline and loss of inde-
pendence if they are hospitalised.
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